Global and Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, Status and Forecast 2020-2026
SKU ID : QYR-16352173 | Publishing Date : 01-Sep-2020 | No. of pages : 93
Detailed TOC of Global and Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, Status and Forecast 2020-2026
1 Report Overview1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate by Type: 2020 VS 2026
1.2.2 Vitamin E & Pioglitazone
1.2.3 Obeticholic Acid (OCA)
1.2.4 Elafibranor
1.2.5 Selonsertib & Cenicriviroc
1.3 Market by Application
1.3.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application: 2020 VS 2026
1.3.2 Hospital Pharmacy
1.3.3 Online Provider
1.3.4 Retail Pharmacy
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Perspective (2015-2026)
2.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Growth Trends by Regions
2.2.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Historic Market Share by Regions (2015-2020)
2.2.3 Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players by Market Size
3.1.1 Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players by Revenue (2015-2020)
3.1.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Players (2015-2020)
3.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue
3.4 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Concentration Ratio
3.4.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in 2019
3.5 Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Area Served
3.6 Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Product Solution and Service
3.7 Date of Enter into Non-Alcoholic Steatohepatitis (NASH) Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-Alcoholic Steatohepatitis (NASH) Drugs Breakdown Data by Type (2015-2026)
4.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Historic Market Size by Type (2015-2020)
4.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Type (2021-2026)
5 Non-Alcoholic Steatohepatitis (NASH) Drugs Breakdown Data by Application (2015-2026)
5.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Historic Market Size by Application (2015-2020)
5.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2015-2026)
6.2 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020)
6.3 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020)
6.4 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2015-2020)
6.4.1 United States
6.4.2 Canada
7 Europe
7.1 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2015-2026)
7.2 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020)
7.3 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020)
7.4 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2015-2020)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
7.4.6 Nordic
7.4.7 Rest of Europe
8 China
8.1 China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2015-2026)
8.2 China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020)
8.3 China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020)
8.4 China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (2015-2020)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 Southeast Asia
8.4.5 India
8.4.6 Australia
8.4.7 Rest of Asia-Pacific
9 Japan
9.1 Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2015-2026)
9.2 Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020)
9.3 Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020)
9.4 Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2015-2020)
9.4.1 Mexico
9.4.2 Brazil
10 Southeast Asia
10.1 Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2015-2026)
10.2 Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020)
10.3 Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020)
10.4 Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2015-2020)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
10.4.4 Rest of Middle East & Africa
11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Details
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
11.1.4 AstraZeneca Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020))
11.1.5 AstraZeneca Recent Development
11.2 Conatus Pharmaceuticals
11.2.1 Conatus Pharmaceuticals Company Details
11.2.2 Conatus Pharmaceuticals Business Overview
11.2.3 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
11.2.4 Conatus Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
11.2.5 Conatus Pharmaceuticals Recent Development
11.3 Enzo Biochem
11.3.1 Enzo Biochem Company Details
11.3.2 Enzo Biochem Business Overview
11.3.3 Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
11.3.4 Enzo Biochem Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
11.3.5 Enzo Biochem Recent Development
11.4 Galmed Pharmaceuticals
11.4.1 Galmed Pharmaceuticals Company Details
11.4.2 Galmed Pharmaceuticals Business Overview
11.4.3 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
11.4.4 Galmed Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
11.4.5 Galmed Pharmaceuticals Recent Development
11.5 Genfit
11.5.1 Genfit Company Details
11.5.2 Genfit Business Overview
11.5.3 Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
11.5.4 Genfit Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
11.5.5 Genfit Recent Development
11.6 Gilead
11.6.1 Gilead Company Details
11.6.2 Gilead Business Overview
11.6.3 Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
11.6.4 Gilead Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
11.6.5 Gilead Recent Development
11.7 Horizon Pharma
11.7.1 Horizon Pharma Company Details
11.7.2 Horizon Pharma Business Overview
11.7.3 Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
11.7.4 Horizon Pharma Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
11.7.5 Horizon Pharma Recent Development
11.8 Immuron
11.8.1 Immuron Company Details
11.8.2 Immuron Business Overview
11.8.3 Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
11.8.4 Immuron Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
11.8.5 Immuron Recent Development
11.9 Intercept Pharmaceuticals
11.9.1 Intercept Pharmaceuticals Company Details
11.9.2 Intercept Pharmaceuticals Business Overview
11.9.3 Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
11.9.4 Intercept Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
11.9.5 Intercept Pharmaceuticals Recent Development
11.10 Novo Nordisk
11.10.1 Novo Nordisk Company Details
11.10.2 Novo Nordisk Business Overview
11.10.3 Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
11.10.4 Novo Nordisk Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
11.10.5 Novo Nordisk Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Figures, Tables and Charts Available in Global and Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, Status and Forecast 2020-2026
List of TablesTable 1. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 3. Key Players of Vitamin E & Pioglitazone
Table 4. Key Players of Obeticholic Acid (OCA)
Table 5. Key Players of Elafibranor
Table 6. Key Players of Selonsertib & Cenicriviroc
Table 7. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 8. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Regions (US$ Million): 2020 VS 2026
Table 9. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Regions (2015-2020) (US$ Million)
Table 10. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Regions (2015-2020)
Table 11. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 12. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Regions (2021-2026)
Table 13. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Market Trends
Table 14. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Drivers
Table 15. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Challenges
Table 16. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Restraints
Table 17. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Players (2015-2020) (US$ Million)
Table 18. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Players (2015-2020)
Table 19. Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs as of 2019)
Table 20. Global Non-Alcoholic Steatohepatitis (NASH) Drugs by Players Market Concentration Ratio (CR5 and HHI)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Product Solution and Service
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020) (US$ Million)
Table 25. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Share by Type (2015-2020)
Table 26. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Type (2021-2026)
Table 27. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Share by Application (2015-2020)
Table 28. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020) (US$ Million)
Table 29. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Share by Application (2021-2026)
Table 30. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020) (US$ Million)
Table 31. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type (2015-2020)
Table 32. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020) (US$ Million)
Table 33. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application (2015-2020)
Table 34. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (US$ Million) (2015-2020)
Table 35. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Country (2015-2020)
Table 36. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020) (US$ Million)
Table 37. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type (2015-2020)
Table 38. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020) (US$ Million)
Table 39. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application (2015-2020)
Table 40. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (US$ Million) (2015-2020)
Table 41. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Country (2015-2020)
Table 42. China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020) (US$ Million)
Table 43. China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type (2015-2020)
Table 44. China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020) (US$ Million)
Table 45. China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application (2015-2020)
Table 46. China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (US$ Million) (2015-2020)
Table 47. China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Region (2015-2020)
Table 48. Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020) (US$ Million)
Table 49. Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type (2015-2020)
Table 50. Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020) (US$ Million)
Table 51. Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application (2015-2020)
Table 52. Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (US$ Million) (2015-2020)
Table 53. Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Country (2015-2020)
Table 54. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020) (US$ Million)
Table 55. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type (2015-2020)
Table 56. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020) (US$ Million)
Table 57. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application (2015-2020)
Table 58. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (US$ Million) (2015-2020)
Table 59. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Country (2015-2020)
Table 60. AstraZeneca Company Details
Table 61. AstraZeneca Business Overview
Table 62. AstraZeneca Product
Table 63. AstraZeneca Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) (US$ Million)
Table 64. AstraZeneca Recent Development
Table 65. Conatus Pharmaceuticals Company Details
Table 66. Conatus Pharmaceuticals Business Overview
Table 67. Conatus Pharmaceuticals Product
Table 68. Conatus Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) (US$ Million)
Table 69. Conatus Pharmaceuticals Recent Development
Table 70. Enzo Biochem Company Details
Table 71. Enzo Biochem Business Overview
Table 72. Enzo Biochem Product
Table 73. Enzo Biochem Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) (US$ Million)
Table 74. Enzo Biochem Recent Development
Table 75. Galmed Pharmaceuticals Company Details
Table 76. Galmed Pharmaceuticals Business Overview
Table 77. Galmed Pharmaceuticals Product
Table 78. Galmed Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) (US$ Million)
Table 79. Galmed Pharmaceuticals Recent Development
Table 80. Genfit Company Details
Table 81. Genfit Business Overview
Table 82. Genfit Product
Table 83. Genfit Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) (US$ Million)
Table 84. Genfit Recent Development
Table 85. Gilead Company Details
Table 86. Gilead Business Overview
Table 87. Gilead Product
Table 88. Gilead Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) (US$ Million)
Table 89. Gilead Recent Development
Table 90. Horizon Pharma Company Details
Table 91. Horizon Pharma Business Overview
Table 92. Horizon Pharma Product
Table 93. Horizon Pharma Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) (US$ Million)
Table 94. Horizon Pharma Recent Development
Table 95. Immuron Business Overview
Table 96. Immuron Product
Table 97. Immuron Company Details
Table 98. Immuron Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) (US$ Million)
Table 99. Immuron Recent Development
Table 100. Intercept Pharmaceuticals Company Details
Table 101. Intercept Pharmaceuticals Business Overview
Table 102. Intercept Pharmaceuticals Product
Table 103. Intercept Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) (US$ Million)
Table 104. Intercept Pharmaceuticals Recent Development
Table 105. Novo Nordisk Company Details
Table 106. Novo Nordisk Business Overview
Table 107. Novo Nordisk Product
Table 108. Novo Nordisk Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) (US$ Million)
Table 109. Novo Nordisk Recent Development
Table 110. Research Programs/Design for This Report
Table 111. Key Data Information from Secondary Sources
Table 112. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type: 2020 VS 2026
Figure 2. Vitamin E & Pioglitazone Features
Figure 3. Obeticholic Acid (OCA) Features
Figure 4. Elafibranor Features
Figure 5. Selonsertib & Cenicriviroc Features
Figure 6. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application: 2020 VS 2026
Figure 7. Hospital Pharmacy Case Studies
Figure 8. Online Provider Case Studies
Figure 9. Retail Pharmacy Case Studies
Figure 10. Non-Alcoholic Steatohepatitis (NASH) Drugs Report Years Considered
Figure 11. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (US$ Million), YoY Growth 2015-2026
Figure 12. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Regions: 2020 VS 2026
Figure 13. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Regions (2021-2026)
Figure 14. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Players in 2019
Figure 15. Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs as of 2019
Figure 16. The Top 10 and 5 Players Market Share by Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in 2019
Figure 17. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 18. United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 19. Canada Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 20. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 21. Germany Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 22. France Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 23. U.K. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 24. Italy Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 25. Russia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 26. Nordic Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 27. Rest of Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 28. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 29. China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 30. Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 31. South Korea Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 32. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 33. India Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 34. Australia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 35. Rest of Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 36. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 37. Mexico Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 38. Brazil Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 39. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 40. Turkey Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 41. Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 42. UAE Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 43. Rest of Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 44. AstraZeneca Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
Figure 45. Conatus Pharmaceuticals Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
Figure 46. Enzo Biochem Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
Figure 47. Galmed Pharmaceuticals Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
Figure 48. Genfit Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
Figure 49. Gilead Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
Figure 50. Horizon Pharma Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
Figure 51. Immuron Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
Figure 52. Intercept Pharmaceuticals Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
Figure 53. Novo Nordisk Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
Figure 54. Bottom-up and Top-down Approaches for This Report
Figure 55. Data Triangulation
Figure 56. Key Executives Interviewed
Keyplayers in Global and Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, Status and Forecast 2020-2026
AstraZenecaConatus Pharmaceuticals
Enzo Biochem
Galmed Pharmaceuticals
Genfit
Gilead
Horizon Pharma
Immuron
Intercept Pharmaceuticals
Novo Nordisk